Literature DB >> 10727521

Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor.

M H Rhee1, I Nevo, T Avidor-Reiss, R Levy, Z Vogel.   

Abstract

Many types of cells exhibit increased adenylyl cyclase (AC) activity after chronic agonist treatment of G(i/o)-coupled receptors. This phenomenon, defined as AC superactivation or sensitization, has mostly been studied for the opioid receptors and is implicated in opiate addiction. Here we show that this phenomenon is also observed on chronic activation of the CB(1) cannabinoid receptor. Moreover, using COS-7 cells cotransfected with CB(1) receptor and individual AC isozymes, we could show selective superactivation of AC types I, III, V, VI, and VIII. The level of superactivation was dependent on the concentration of agonist and time of agonist exposure and was not dependent on the AC stimulator used. No superactivation of AC types II, IV, or VII was observed in COS-7 cells cotransfected with CB(1). The superactivation of AC type V was abolished by pretreatment with pertussis toxin and by cotransfection with the carboxy terminus of beta-adrenergic receptor kinase, which serves as a scavenger of G(betagamma) dimers, implying a role for the G(i/o) proteins and especially G(betagamma) dimers in the cannabinoid-induced superactivation of AC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727521     DOI: 10.1124/mol.57.4.746

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens.

Authors:  D Robbe; G Alonso; F Duchamp; J Bockaert; O J Manzoni
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 2.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Regulation of adenylate cyclase type VIII splice variants by acute and chronic Gi/o-coupled receptor activation.

Authors:  Debora Steiner; Tomer Avidor-Reiss; Ester Schallmach; Elena Butovsky; Nirit Lev; Zvi Vogel
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

4.  Inhibition and superactivation of the calcium-stimulated isoforms of adenylyl cyclase: role of Gbetagamma dimers.

Authors:  Debora Steiner; Tomer Avidor-Reiss; Ester Schallmach; Daniella Saya; Zvi Vogel
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.

Authors:  Christine Börner; Michal Smida; Volker Höllt; Burkhart Schraven; Jürgen Kraus
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

6.  Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells.

Authors:  Andrea L Small-Howard; Lori M N Shimoda; Chaker N Adra; Helen Turner
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

7.  delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.

Authors:  Laura E Wise; Stephen A Varvel; Dana E Selley; Jason M Wiebelhaus; Kelly A Long; Lisa S Middleton; Laura J Sim-Selley; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2011-05-11       Impact factor: 4.530

Review 8.  Gα(i/o)-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later.

Authors:  Tarsis F Brust; Jason M Conley; Val J Watts
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

Review 9.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 10.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.